Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00 -0.23% 3,490.00 3,490.00 3,492.00 3,534.00 3,478.00 3,534.00 61,515 09:15:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 515.1 40.9 32.9 106.2 3,780

Dechra Pharmaceuticals Share Discussion Threads

Showing 501 to 522 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
16/9/2020
08:31
IMO a firm hold and forget. People love their pets as much as their family.
johnrxx99
07/9/2020
07:56
The interim dividend was up 8.3% so the final dividend has been increased by a similar amount.The earnings figures are modestly ie about 2% better than consensus,broadly in line.
steeplejack
07/9/2020
07:50
Was the increased dividend expected?
lasata
07/9/2020
07:40
I think a company that increases profits in the current environment is fairly 'special'.The shares are highly rated but justifiably.
steeplejack
07/9/2020
07:34
Ok results...nothing special. Good to see dividend is up
lasata
09/7/2020
14:11
"Trading in the year was robust and in line with management expectations."Preliminary results,Monday 7 Sept 2020.
steeplejack
08/7/2020
08:44
Has anyone else picked up on this news from MWI in the US? Working with a UK plc premier?? Interesting....this stock is only 40p with a high of £2+ hxxps://www.mwiah.com/newsroom/press-releases/mwi-animal-health-announces-new-offerings-to-alleviate-financial-burdens-of-pet-care
1hjones
08/7/2020
08:44
Has anyone else picked up on this news from MWI in the US? Working with a UK plc premier?? Interesting....this stock is only 40p with a high of £2+ hxxps://www.mwiah.com/newsroom/press-releases/mwi-animal-health-announces-new-offerings-to-alleviate-financial-burdens-of-pet-care
1hjones
29/6/2020
09:33
Indeed,grandma and pa get stuck in a second rate care home while the pooch gets a cuddle on the sofa.Its a furry thing I guess plus animals are generally more loyal than human beings who are emotionally shifty :)
steeplejack
29/6/2020
08:43
Yes. One of my largest holdings. Owners don't skimp when it comes to their pets. Quite right too.
lindowcross
04/6/2020
07:25
Oh so quiet on here - love it.
johnrxx99
20/5/2020
10:19
Come back is impressive - nearly an Omaha quality.
johnrxx99
21/10/2019
10:28
Problem is crazy high p.e, any hiccup shareprice gets hit hard.
montyhedge
15/9/2019
12:48
Turnover PS 469.35 p Pre-Tax Profit PS 27.08 p Retained Profit PS 2.44 p Cash PS 78.23 p Net Cash PS -36.82 p Net Tangible Asset Value PS * -173.30 p Net Asset Value PS 495.95 p
sarkasm
15/9/2019
12:46
Https://www.marketscreener.com/DECHRA-PHARMACEUTICALS-4003059/?type_recherche=rapide&mots=DPH Summary The company has poor fundamentals for a short-term investment strategy. Strengths Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock. Over the past year, analysts have regularly revised upwards their sales forecast for the company. Analysts covering this company mostly recommend stock overweighting or purchase. Within the weekly time frame the stock shows a bullish technical configuration above the support level at 2478 GBp Weaknesses Stock prices approach a strong long-term resistance in weekly data at GBp 3036. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity. Based on current prices, the company has particularly high valuation levels. The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 90.41 times its estimated earnings per share for the ongoing year. The firm pays small or no dividend to shareholders. For that reason, it is not a yield company. For the past seven days, analysts have been lowering their EPS expectations for the company. For the last few months, analysts have been revising downwards their earnings forecast.
sarkasm
15/9/2019
12:44
MIDAS SHARE TIPS UPDATE: Drugs for pets firm Dechra Pharmaceuticals booms By Joanne Hart for The Mail on Sunday Published: 11:30 BST, 15 September 2019 | Updated: 11:30 BST, 15 September 2019 e-mail View comments Dogs have always played an important role in Korean life. Once, they were a feature on restaurant menus. Today, they are more often seen at the end of a lead. The shift is part of a broader trend across emerging markets, as pet ownership becomes something of a status symbol among aspiring consumers. The more people own cats and dogs, the more they spend on looking after them, to the benefit of Dechra Pharmaceuticals, which makes and sells drugs for pets and other animals. The more people own cats and dogs, the more they spend on looking after them, to the benefit of Dechra Pharmaceuticals, which makes and sells drugs for pets and other animals +1 Drugs business: The more people own cats and dogs, the more they spend on looking after them Midas originally recommended the stock in 2008, when it was £3.97. We recommended it again in 2015, by which time the price had surged to £9.85. Last Friday, the shares closed at £28.90, having almost tripled in the past four years alone. Looking ahead, long-standing chief executive Ian Page is optimistic and recent figures suggest he has good reason to be. RELATED ARTICLES Previous 1 Next MIDAS SHARE TIPS: Here's a VERY hot tip - Filta fryer... MIDAS SHARE TIPS: Want a rock solid shelter? This new... Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) DIY investing Isa - and our pick of the platforms Dechra Pharmaceuticals: Latest price and charts Annual results to June 30, released earlier this month, showed a 17.5 per cent increase in revenues to £482 million, a 27 per cent rise in underlying profits to £127 million and a 24 per cent hike in the dividend to 31.6p. The company’s performance is all the more impressive, as many peers have struggled recently, and Dechra itself has had to cope with increasingly stringent regulation and potential issues around a No Deal Brexit. Free investing guides The group’s resilience derives largely from a simple but effective strategy: listening to what vets need and creating products that satisfy those needs, particularly in specialist areas. Dechra’s best-selling drug, for example, is Vetoryl, used to treat dogs with Cushing’s disease, a hormonal disorder. Initially, Dechra operated only in the UK. Today, it sells to vets around the world. Just over 70 per cent of sales relate to pets, but the group generates strong growth from farm animal and horse products too. Dechra manufactures half the drugs that it sells and buys the rest from third-party producers. Over time, Page would like to make more drugs in-house and the company has a strong pipeline, including a diabetes treatment for cats and dogs that can be injected weekly instead of daily – a clear bonus for pets and their owners. Growth is also likely to come from more geographic expansion and well-chosen acquisitions, as Page has bought several businesses over the years and successfully integrated them into the business. Brokers forecast a continued increase in sales, profits and dividends next year and beyond. MIDAS VERDICT Dechra has come a long way since chief executive Ian Page took the helm in 2001, enjoying 17 years of consistent, double-digit earnings growth. Investors who bought in 2008 – and later in 2015 – have done well and may choose to bank some profits. But most analysts believe the stock could hit £33 in the next year or two so shareholders should retain most of their stock.
sarkasm
02/9/2019
11:33
Main risk here is the company becoming a takeover target in its own right.
bonzo
02/9/2019
07:54
"The Group has delivered another strong performance throughout the financial year. We have continued to outperform in almost all markets in which we operate and strategically it has also been an excellent year." Ian Page, Chief Executive Officer Sept 2nd 2019
steeplejack
29/8/2019
13:05
Massive news here. This will transform the company in the long term.
bonzo
26/7/2019
02:29
Like the look of these.
discodave45
03/6/2019
12:13
Well up with events, no room for disappointments.
montyhedge
25/3/2019
17:17
Analysts at JPMorgan Cazenove initiated coverage on Dechra Pharmaceuticals at 'overweight' on Monday, calling the veterinary products manufacturer a "diamond in the ruff".JPM, which sees animal health as an "attractive" healthcare subsector, said the industry was "fragmented" and felt Dechra was Dechra highly capable of creating "significant value" through mergers and acquisitions.The investment bank's analysts saw attraction in the animal health industry as a result of its strong demographic demand, increasing spend per pet, and increasing animal protein consumption.Low development costs are another appealing element for the analysts, with the FTSE 250 constituent only needing to reinvest around 5% of revenues, and the sector's "superior sustainability" when compared to human pharmaceuticals, with "far more modest genericisations".The analysts, which issued Dechra a twelve-month target price of £30, expect to see Dechra's core EPS grow 11% between 2020 and 2023E, driven by a combination of "strong growth in demand for pet medications" and 200bps worth of operating margin expansion."We see potential forecast upside from pipeline optionality and M&A. We set a Jun-20 PT of £30, 26x 2021E Core-PE, justified by the strong base business outlook, and upside optionality," concluded JPM.
steeplejack
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
ADVFN Advertorial
Your Recent History
LSE
DPH
Dechra Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201021 08:31:47